Biomarkers for Prostate Cancer Detection

Dipen J Parekh, Donna Pauler Ankerst, Dean Troyer, Sudhir Srivastava, Ian M. Thompson

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Purpose: The limitations of prostate specific antigen as a biomarker for prostate cancer screening, characterized by low sensitivity for acceptable false-positive rates, are well known. New markers that differentiate indolent from aggressive cancers to decrease potential the over treatment of prostate cancer are needed. We reviewed current and potential biomarkers for prostate cancer detection. Materials and Methods: A literature search was performed to identify established and emerging biomarkers for prostate cancer detection. Recent suggested guidelines by the Early Detection Research Network for phases of biomarker studies were interpreted for use in prostate cancer and the existing status of marker studies were reviewed with respect to these phases of study. Results: Advances in high throughput bench research, including high dimensional genomic, proteomic and autoantibody signatures, have the potential to improve the operating characteristics of prostate specific antigen but they are undergoing reproducibility and multicenter validation studies. None of the prostate specific antigen derivatives or isoforms, such as prostate specific antigen density, velocity or percent complexed prostate specific antigen, improve operating characteristics enough to likely replace prostate specific antigen. Prostate stem cell antigen, alpha-methyl coenzyme-A racemase, PCA3, early prostate cancer antigen, human kallikrein 2 and hepsin are promising markers that are currently undergoing validation. Conclusions: The process of discovering novel biomarkers to replace or augment the existing best marker, prostate specific antigen, requires standardized phases of evaluation and validation. Several biomarkers are currently on the cusp of initial validation studies.

Original languageEnglish
Pages (from-to)2252-2259
Number of pages8
JournalJournal of Urology
Volume178
Issue number6
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Biomarkers
Validation Studies
Racemases and Epimerases
Tissue Kallikreins
Coenzymes
Early Detection of Cancer
Research
Autoantibodies
Proteomics
Multicenter Studies
Prostate
Protein Isoforms
Stem Cells
Guidelines
Antigens
Neoplasms

Keywords

  • biological
  • prostate
  • prostate-specific antigen
  • prostatic neoplasms
  • tumor markers
  • validation studies [publication type]

ASJC Scopus subject areas

  • Urology

Cite this

Parekh, D. J., Ankerst, D. P., Troyer, D., Srivastava, S., & Thompson, I. M. (2007). Biomarkers for Prostate Cancer Detection. Journal of Urology, 178(6), 2252-2259. https://doi.org/10.1016/j.juro.2007.08.055

Biomarkers for Prostate Cancer Detection. / Parekh, Dipen J; Ankerst, Donna Pauler; Troyer, Dean; Srivastava, Sudhir; Thompson, Ian M.

In: Journal of Urology, Vol. 178, No. 6, 01.12.2007, p. 2252-2259.

Research output: Contribution to journalArticle

Parekh, DJ, Ankerst, DP, Troyer, D, Srivastava, S & Thompson, IM 2007, 'Biomarkers for Prostate Cancer Detection', Journal of Urology, vol. 178, no. 6, pp. 2252-2259. https://doi.org/10.1016/j.juro.2007.08.055
Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson IM. Biomarkers for Prostate Cancer Detection. Journal of Urology. 2007 Dec 1;178(6):2252-2259. https://doi.org/10.1016/j.juro.2007.08.055
Parekh, Dipen J ; Ankerst, Donna Pauler ; Troyer, Dean ; Srivastava, Sudhir ; Thompson, Ian M. / Biomarkers for Prostate Cancer Detection. In: Journal of Urology. 2007 ; Vol. 178, No. 6. pp. 2252-2259.
@article{36d50773a3974b759855d1bf60ddcd7b,
title = "Biomarkers for Prostate Cancer Detection",
abstract = "Purpose: The limitations of prostate specific antigen as a biomarker for prostate cancer screening, characterized by low sensitivity for acceptable false-positive rates, are well known. New markers that differentiate indolent from aggressive cancers to decrease potential the over treatment of prostate cancer are needed. We reviewed current and potential biomarkers for prostate cancer detection. Materials and Methods: A literature search was performed to identify established and emerging biomarkers for prostate cancer detection. Recent suggested guidelines by the Early Detection Research Network for phases of biomarker studies were interpreted for use in prostate cancer and the existing status of marker studies were reviewed with respect to these phases of study. Results: Advances in high throughput bench research, including high dimensional genomic, proteomic and autoantibody signatures, have the potential to improve the operating characteristics of prostate specific antigen but they are undergoing reproducibility and multicenter validation studies. None of the prostate specific antigen derivatives or isoforms, such as prostate specific antigen density, velocity or percent complexed prostate specific antigen, improve operating characteristics enough to likely replace prostate specific antigen. Prostate stem cell antigen, alpha-methyl coenzyme-A racemase, PCA3, early prostate cancer antigen, human kallikrein 2 and hepsin are promising markers that are currently undergoing validation. Conclusions: The process of discovering novel biomarkers to replace or augment the existing best marker, prostate specific antigen, requires standardized phases of evaluation and validation. Several biomarkers are currently on the cusp of initial validation studies.",
keywords = "biological, prostate, prostate-specific antigen, prostatic neoplasms, tumor markers, validation studies [publication type]",
author = "Parekh, {Dipen J} and Ankerst, {Donna Pauler} and Dean Troyer and Sudhir Srivastava and Thompson, {Ian M.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/j.juro.2007.08.055",
language = "English",
volume = "178",
pages = "2252--2259",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Biomarkers for Prostate Cancer Detection

AU - Parekh, Dipen J

AU - Ankerst, Donna Pauler

AU - Troyer, Dean

AU - Srivastava, Sudhir

AU - Thompson, Ian M.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Purpose: The limitations of prostate specific antigen as a biomarker for prostate cancer screening, characterized by low sensitivity for acceptable false-positive rates, are well known. New markers that differentiate indolent from aggressive cancers to decrease potential the over treatment of prostate cancer are needed. We reviewed current and potential biomarkers for prostate cancer detection. Materials and Methods: A literature search was performed to identify established and emerging biomarkers for prostate cancer detection. Recent suggested guidelines by the Early Detection Research Network for phases of biomarker studies were interpreted for use in prostate cancer and the existing status of marker studies were reviewed with respect to these phases of study. Results: Advances in high throughput bench research, including high dimensional genomic, proteomic and autoantibody signatures, have the potential to improve the operating characteristics of prostate specific antigen but they are undergoing reproducibility and multicenter validation studies. None of the prostate specific antigen derivatives or isoforms, such as prostate specific antigen density, velocity or percent complexed prostate specific antigen, improve operating characteristics enough to likely replace prostate specific antigen. Prostate stem cell antigen, alpha-methyl coenzyme-A racemase, PCA3, early prostate cancer antigen, human kallikrein 2 and hepsin are promising markers that are currently undergoing validation. Conclusions: The process of discovering novel biomarkers to replace or augment the existing best marker, prostate specific antigen, requires standardized phases of evaluation and validation. Several biomarkers are currently on the cusp of initial validation studies.

AB - Purpose: The limitations of prostate specific antigen as a biomarker for prostate cancer screening, characterized by low sensitivity for acceptable false-positive rates, are well known. New markers that differentiate indolent from aggressive cancers to decrease potential the over treatment of prostate cancer are needed. We reviewed current and potential biomarkers for prostate cancer detection. Materials and Methods: A literature search was performed to identify established and emerging biomarkers for prostate cancer detection. Recent suggested guidelines by the Early Detection Research Network for phases of biomarker studies were interpreted for use in prostate cancer and the existing status of marker studies were reviewed with respect to these phases of study. Results: Advances in high throughput bench research, including high dimensional genomic, proteomic and autoantibody signatures, have the potential to improve the operating characteristics of prostate specific antigen but they are undergoing reproducibility and multicenter validation studies. None of the prostate specific antigen derivatives or isoforms, such as prostate specific antigen density, velocity or percent complexed prostate specific antigen, improve operating characteristics enough to likely replace prostate specific antigen. Prostate stem cell antigen, alpha-methyl coenzyme-A racemase, PCA3, early prostate cancer antigen, human kallikrein 2 and hepsin are promising markers that are currently undergoing validation. Conclusions: The process of discovering novel biomarkers to replace or augment the existing best marker, prostate specific antigen, requires standardized phases of evaluation and validation. Several biomarkers are currently on the cusp of initial validation studies.

KW - biological

KW - prostate

KW - prostate-specific antigen

KW - prostatic neoplasms

KW - tumor markers

KW - validation studies [publication type]

UR - http://www.scopus.com/inward/record.url?scp=35748956714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748956714&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2007.08.055

DO - 10.1016/j.juro.2007.08.055

M3 - Article

C2 - 17936845

AN - SCOPUS:35748956714

VL - 178

SP - 2252

EP - 2259

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -